Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: infectious disease vaccines - iBio

Next Previous
Drug Profile

Research programme: infectious disease vaccines - iBio

Alternative Names: Anthrax vaccine - iBio; Anthrax-plague combination vaccine - iBio; Cancer vaccine - iBio; HPV vaccine - iBio; Influenza A virus H7N9 vaccine - iBio; Malaria vaccine - iBio; Plague vaccine - iBio

Latest Information Update: 28 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INB:Biotechnologies
  • Developer iBio Inc
  • Class Anthrax vaccines; Cancer vaccines; Influenza A virus H7N9 vaccines; Papillomavirus vaccines; Parasitic vaccines; Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Bacterial infections; Parasitic infections; Viral infections

Highest Development Phases

  • No development reported Anthrax; Cancer; Human papillomavirus infections; Influenza A virus H7N9 subtype; Plague

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in USA
  • 18 Oct 2016 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top